The global Malaria Vaccine Market is valued at USD 394.4 Million in 2021 and is expected to reach USD 887.8 Million by 2028 with a CAGR of 12.3% over the forecast period.
Global Malaria Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of malaria, rising number of clinical trials for malarial vaccines and growing number of government initiatives for controlling the spread of malaria are major factors driving the growth of the Global Malaria Vaccines Market within the forecast period.
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. The major symptom of malaria are; high fever, weakness and chills. A malaria vaccine is use to prevent malaria. The disease is common in subtropical regions Sub-Saharan Africa, South and Southeast Asia, Pacific Islands and Central America and northern South America. Malaria can be deadly, predominantly when caused by the plasmodium species common in Africa. The research on developing malarial vaccine has been going since 1960s. However, October 6th, 2021; will be remarkable day for in the development of malaria vaccines, as Mosquirix vaccine is approved by World Health Organization (WHO). Also, research on other malaria vaccines is still going on. The malarial vaccine is safe and cost effective.
The Covid-19 pandemic has also impacted on the global malaria vaccine market. During COVID-19 pandemic, research and development activities for malaria vaccine were slowed down because of entire focus of medical and healthcare was shifted on Covid- vaccine development. Due to the supply chain disruptions and travelling restrictions, there was a lack of raw material for vaccine development and which has affected the market growth during pandemic.
The global malaria vaccine market is segmented on the basis of by the type of agent, type, end-user, and region & country level. On the basis of agent type, the market is segmented into plasmodium falciparum, plasmodium vivax and anopheles’ species. On the basis of type, the market is segmented into the pre-erythrocytic vaccines, erythrocytic vaccine and multi-antigen vaccine. On the basis of end-users, the global malaria vaccines market is segmented into hospitals, clinics and community centers.
Some of the key players of global malaria vaccines market are
On July 27th, 2021; BioNTech built its achievement in Covid-19 by fostering the primary vaccine for malaria dependent on mRNA innovation and aims to begin clinical testing by the end on 2022, trying to destroy the mosquito-borne diseases. Malaria is a complex contamination brought about by a parasite that avoids recognition by the immune system, adding the objective is to develop an vaccine that makes the parasite apparent and attackable from the beginning. Messenger RNA vaccines brief the human body to make a protein that is important for the microorganism, setting off an immune response. They are additionally quicker to develop than traditional vaccines & can be adjusted moderately without any problem.
On January 28th, 2021; Bharat Biotech International and GlaxoSmithKline plc signed an agreement to get technology from GSK to supply the world’s first vaccine against malaria caused by plasmodium falciparum parasite. According to the agreement, Bharat Biotech gets transport of the developed the antigen part of the malaria vaccine (RTS, S/AS01E) and the grant of a license on all rights about the malaria vaccine, while GSK will keep the assembly of adjuvant of the vaccine to give to the Indian vaccine producer.
One of the major factors driving the growth of the global malaria vaccine market is increasing prevalence of malaria. Vaccines are the preventive measures for the disease. The vaccine targets the parasite Plasmodium falciparum. Thus, increasing cases of malaria lead to increase the demand for malaria vaccines. For instance; according to World Health Organization (WHO); there have been 241 million cases of malaria worldwide in 2020. In addition, rising number of clinical trials of malarial vaccines are also supplementing the market growth. Increasing need for effective vaccine development to fight against devastating malaria has been fuelling the market growth. For instance; as per the news published on October 21st , 2021, Griffith University researchers did clinical trials for the development of a broad-spectrum vaccine that can be freeze-dried making it suitable for deployment into malaria-endemic countries. This new malaria vaccine candidate presents a significant advance in the fight against a highly impactful disease driving the market growth.
Furthermore, growing number of supportive government initiatives for controlling the spread of malaria also drives the global malaria vaccines market. For instance; World Health Organization (WHO) developed Global technical strategy for malaria 2016–2030 which provides a technical framework for all malaria-endemic countries. These strategies included reducing malaria case incidence by at least 90% by 2030. Thus, these initiatives by government to control spread of malaria further fueling the growth of the global malaria vaccines market.
However, high cost of malaria vaccine may hamper the growth of the global malaria vaccines market. In spite of that, various organizations and pharmaceutical companies are focusing on research and development of malaria vaccine which can provide various opportunities for the further growth of the global malaria vaccines market.
Middle East and Africa has shown a significant growth in the global malaria vaccines market due to increasing prevalence of malaria, rising number of malaria awareness programs, accessibility of diagnostic tests for the disease, and government initiatives to control and of malaria across this region. For instance; in 2018, according to the World Health Organization (WHO), about 265,000 African children died because of malaria. In addition to that, increasing number of initiatives taken by the government such as; malaria awareness programs area also supplementing the market growth. And, the World Health Organization made an important announcement, recommending the first-ever malaria vaccine, RTS, S, among children in sub-Saharan Africa. Subsequently in 2019, about 2.3 million doses of the new vaccine Mosquirix have been given to infants in Ghana, Kenya and Malawi in a large-scale pilot programme coordinated by the WHO. These initiatives further boosting the market growth in the Middle East & Africa region.
Asia Pacific region is expected to grow at the fastest rate in the global malaria vaccine market due to the increasing number of malarial infections, rising population and increasing government initiative for disease control in this region. In Asia Pacific, India is one of the highly affected countries by malaria. For instance; in 2020 there have been 20 million cases of malaria according to the World Malaria Report 2020. Also, Indian government launched different programmes for the control of malaria in India. For example; in July 2019, Indian government implemented the HBHI initiative started in four states West Bengal, Jharkhand, Chhattisgarh, and Madhya Pradesh. Asia Pacific Leaders Malaria Alliance (APLMA) which has target of malaria elimination in all countries of the Asia Pacific region by 2030.
|2015 - 2020
|2021 - 2028
|Market Size in 2021:
|USD 394.4 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 887.8 Million
|Tables, Charts & Figures:
|Key Players / Manufacturers
|CellFree Sciences Co. Ltd., Sanaria Inc, Nobelpharma Co, VLP Therapeutics LLC, Cadila Healthcare Ltd., Genome ReS Ltd., Biotech, GenVec, GlaxoSmithKline plc. and others.
|By Agent Type, By Type, By End-Users
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®